Walter Public Investments Inc. Has $2.88 Million Position in IDEXX Laboratories, Inc. $IDXX

Walter Public Investments Inc. cut its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 48.7% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 5,116 shares of the company’s stock after selling 4,847 shares during the quarter. Walter Public Investments Inc.’s holdings in IDEXX Laboratories were worth $2,875,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in IDXX. Howe & Rusling Inc. boosted its position in IDEXX Laboratories by 1.8% in the first quarter. Howe & Rusling Inc. now owns 9,815 shares of the company’s stock valued at $5,515,000 after buying an additional 172 shares in the last quarter. Montrusco Bolton Investments Inc. increased its holdings in shares of IDEXX Laboratories by 93.4% during the first quarter. Montrusco Bolton Investments Inc. now owns 342,120 shares of the company’s stock worth $186,707,000 after buying an additional 165,188 shares in the last quarter. QRG Capital Management Inc. lifted its stake in shares of IDEXX Laboratories by 14.0% in the 1st quarter. QRG Capital Management Inc. now owns 2,846 shares of the company’s stock valued at $1,599,000 after acquiring an additional 350 shares during the last quarter. HB Wealth Management LLC boosted its holdings in shares of IDEXX Laboratories by 3.3% during the 1st quarter. HB Wealth Management LLC now owns 4,277 shares of the company’s stock valued at $2,404,000 after acquiring an additional 138 shares in the last quarter. Finally, Moran Wealth Management LLC boosted its holdings in shares of IDEXX Laboratories by 4.7% during the 1st quarter. Moran Wealth Management LLC now owns 13,128 shares of the company’s stock valued at $7,376,000 after acquiring an additional 585 shares in the last quarter. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts have issued reports on IDXX shares. Citigroup began coverage on IDEXX Laboratories in a report on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 target price for the company. Stifel Nicolaus reduced their price target on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a report on Tuesday, March 31st. UBS Group lowered their price objective on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a research note on Tuesday, April 28th. Wall Street Zen upgraded shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Saturday, June 13th. Finally, Weiss Ratings upgraded shares of IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, June 25th. Seven analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $751.00.

IDEXX Laboratories Price Performance

Shares of NASDAQ:IDXX opened at $557.80 on Friday. The firm has a market cap of $44.00 billion, a P/E ratio of 41.08, a P/E/G ratio of 3.05 and a beta of 1.55. The company has a quick ratio of 0.82, a current ratio of 1.12 and a debt-to-equity ratio of 0.19. IDEXX Laboratories, Inc. has a 12-month low of $506.91 and a 12-month high of $769.98. The business has a fifty day simple moving average of $555.31 and a 200 day simple moving average of $609.16.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Tuesday, May 5th. The company reported $3.47 EPS for the quarter, topping the consensus estimate of $3.41 by $0.06. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The firm had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.12 billion. During the same period in the previous year, the business earned $2.91 EPS. The business’s quarterly revenue was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Analysts predict that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.